BACKGROUND: Virological monitoring is essential to identify antiretroviral treatment (ART) failure, but not widely available. Here, accumulation of resistance and consequences for second-line therapy were investigated in African HIV-1 subtype-C-infected patients. METHODS: A total of 836 patients initiated non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART and received biannual HIV RNA monitoring. When first-line ART was continued despite virological failure (HIV RNA>1,000 copies/ml), genotypic resistance analysis was performed at baseline, first failure (t1), and 6 or 12 months later (t2). Major resistance mutations (IAS), Stanford genotypic sensitivity scores (GSSs) and proportions of patients meeting WHO-defined failure criteria were compared between time points. RESULTS: Most patients (642/836, 77%) reached viral suppression and 145/642 patients (23%) experienced subsequent failure after a median of 18 months. Counselling resulted in virological re-suppression in 27% (39/145) and 40% (58/145) continued first-line ART despite virological failure; 26 patients were included for genotypic analysis.The mean number of major drug resistance mutations per person increased from 2.8 (t1) to 4.3 (t2). Initially, NNRTI-associated mutations (n=47) predominated; only 25 nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations (mainly M184V) were detected. During prolonged viraemia, NRTI resistance increased (n=44, +76%), in particular thymidine analogue mutations (from 4 to 14) and K65R (from 3 to 6). Consequently, GSSs declined from baseline to t1 and t2: from 3.8 to 1.0 to 0.7 (NNRTIs) and from 6.8 to 5.1 to 4.0 (NRTIs). Despite broad resistance, immunological failure was limited at t2. CONCLUSIONS: Rapid accumulation of drug resistance occurred when ART was continued despite virological failure. Treatment options were lost, even when WHO-defined failure criteria were not met. This study calls for wider access to virological monitoring.
BACKGROUND: Virological monitoring is essential to identify antiretroviral treatment (ART) failure, but not widely available. Here, accumulation of resistance and consequences for second-line therapy were investigated in African HIV-1 subtype-C-infectedpatients. METHODS: A total of 836 patients initiated non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART and received biannual HIV RNA monitoring. When first-line ART was continued despite virological failure (HIV RNA>1,000 copies/ml), genotypic resistance analysis was performed at baseline, first failure (t1), and 6 or 12 months later (t2). Major resistance mutations (IAS), Stanford genotypic sensitivity scores (GSSs) and proportions of patients meeting WHO-defined failure criteria were compared between time points. RESULTS: Most patients (642/836, 77%) reached viral suppression and 145/642 patients (23%) experienced subsequent failure after a median of 18 months. Counselling resulted in virological re-suppression in 27% (39/145) and 40% (58/145) continued first-line ART despite virological failure; 26 patients were included for genotypic analysis.The mean number of major drug resistance mutations per person increased from 2.8 (t1) to 4.3 (t2). Initially, NNRTI-associated mutations (n=47) predominated; only 25 nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations (mainly M184V) were detected. During prolonged viraemia, NRTI resistance increased (n=44, +76%), in particular thymidine analogue mutations (from 4 to 14) and K65R (from 3 to 6). Consequently, GSSs declined from baseline to t1 and t2: from 3.8 to 1.0 to 0.7 (NNRTIs) and from 6.8 to 5.1 to 4.0 (NRTIs). Despite broad resistance, immunological failure was limited at t2. CONCLUSIONS: Rapid accumulation of drug resistance occurred when ART was continued despite virological failure. Treatment options were lost, even when WHO-defined failure criteria were not met. This study calls for wider access to virological monitoring.
Authors: Vinie Kouamou; Justen Manasa; David Katzenstein; Alan M McGregor; Chiratidzo E Ndhlovu; Azure T Makadzange Journal: AIDS Date: 2019-09-01 Impact factor: 4.177
Authors: A D Revell; D Wang; R Wood; C Morrow; H Tempelman; R L Hamers; G Alvarez-Uria; A Streinu-Cercel; L Ene; A M J Wensing; F DeWolf; M Nelson; J S Montaner; H C Lane; B A Larder Journal: J Antimicrob Chemother Date: 2013-03-13 Impact factor: 5.790
Authors: Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega Journal: J Infect Dis Date: 2013-06-15 Impact factor: 5.226
Authors: Isaac Singini; Thomas B Campbell; Laura M Smeaton; Nagalingeswaran Kumarasamy; Alberto La Rosa; Sineenart Taejareonkul; Steven A Safren; Timothy P Flanigan; James G Hakim; Michael D Hughes Journal: HIV Clin Trials Date: 2016-07-29
Authors: Rami Kantor; Laura Smeaton; Saran Vardhanabhuti; Sarah E Hudelson; Carol L Wallis; Srikanth Tripathy; Mariza G Morgado; Shanmugham Saravanan; Pachamuthu Balakrishnan; Marissa Reitsma; Stephen Hart; John W Mellors; Elias Halvas; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Alberto La Rosa; Umesh G Lalloo; Javier R Lama; Mohammed Rassool; Breno R Santos; Khuanchai Supparatpinyo; James Hakim; Timothy Flanigan; Nagalingeswaran Kumarasamy; Thomas B Campbell; Susan H Eshleman Journal: Clin Infect Dis Date: 2015-02-13 Impact factor: 9.079
Authors: F Parker Hudson; Lloyd Mulenga; Andrew O Westfall; Ranjit Warrier; Aggrey Mweemba; Michael S Saag; Jeffrey Sa Stringer; Joseph J Eron; Benjamin H Chi Journal: Antivir Ther Date: 2019